William T. Carpenter

William T. Carpenter's AcademicInfluence.com Rankings

Biology

#3096

World Rank

#4783

Historical Rank

#1301

USA Rank

biology Degrees

Download Badge

Biology

William T. Carpenter's Degrees

Doctorate Medicine University of Pennsylvania
PhD Psychology University of Pennsylvania

Why Is William T. Carpenter Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William T. Carpenter is an American psychiatrist, a pioneer in the fields of psychiatry and pharmacology who served as an expert witness in the John W. Hinckley trial for the attempted assassination of U.S. President Ronald Reagan. His primary professional interest is in severe mental illness, especially schizophrenia, to the prevention and treatment of which he has made significant contributions in psychopathology, assessment methodology, testing of new treatments, and research ethics.

(See a Problem?)

William T. Carpenter's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Remission in schizophrenia: proposed criteria and rationale for consensus. (2005) (2004)
The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. (1984) (1600)
The Hierarchical Taxonomy of Psychopathology (HiTOP): A Dimensional Alternative to Traditional Nosologies (2017) (1554)
ON THE METHODS AND THEORY OF RELIABILITY (1976) (1343)
Deficit and nondeficit forms of schizophrenia: the concept. (1988) (1267)
The psychosis high-risk state: a comprehensive state-of-the-art review. (2013) (1197)
The NIMH-MATRICS consensus statement on negative symptoms. (2006) (1094)
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. (2008) (843)
The prediction of outcome in schizophrenia. I. Characteristics of outcome. (1972) (782)
The schedule for the deficit syndrome: An instrument for research in schizophrenia (1989) (758)
The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. (1974) (620)
A separate disease within the syndrome of schizophrenia. (2001) (617)
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. (2017) (567)
The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. (1974) (555)
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. (1992) (542)
Definition and description of schizophrenia in the DSM-5 (2013) (521)
Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. (1977) (506)
Decisional capacity for informed consent in schizophrenia research. (2000) (498)
Treatment of negative symptoms. (1985) (469)
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. (2015) (468)
Flexible System for the Diagnosis of Schizophrenia: Report from the WHO International Pilot Study of Schizophrenia (1973) (424)
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. (2007) (390)
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. (1994) (385)
Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Schneider's first-rank symptoms. (1973) (334)
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. (2013) (330)
Progress in achieving quantitative classification of psychopathology (2018) (299)
Postpsychotic depression in schizophrenia. (1976) (283)
Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. (1994) (279)
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. (1998) (261)
Structural abnormalities in deficit and nondeficit schizophrenia. (1993) (260)
Diagnostic criteria and five-year outcome in schizophrenia. A report from the International Pilot Study of schizophrenia. (1975) (258)
The Prediction of Outcome in Schizophrenia IV: Eleven‐Year Follow‐Up of the Washington IPSS Cohort (1991) (250)
Domains of Psychopathology: An Approach to the Reduction of Heterogeneity in Schizophrenia (1994) (243)
Exploring the feasibility of a meta-structure for DSM-V and ICD-11: could it improve utility and validity? (2009) (242)
The heterogeneity of the long-term course of schizophrenia. (1988) (240)
Clinical correlates of the deficit syndrome of schizophrenia. (1990) (232)
Diagnosis and classification of schizophrenia. (1993) (209)
Integration and sealing over. Clinically distinct recovery styles from schizophrenia. (1975) (204)
Continuous versus targeted medication in schizophrenic outpatients: outcome results. (1990) (201)
The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities (2008) (201)
At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. (2013) (196)
Cerebrospinal fluid amine metabolites in acute schizophrenia. (1975) (193)
Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. (1976) (191)
Advances in schizophrenia (2001) (191)
Treatment of schizophrenia negative symptoms: future prospects. (2006) (191)
Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: Relevance to DSM-5 (2013) (186)
Structure of the psychotic disorders classification in DSM‐5 (2013) (186)
Catatonia in DSM-5 (2013) (174)
Case identification and stability of the deficit syndrome of schizophrenia (1993) (172)
Factor structure of the brief negative symptom scale (2012) (170)
Attentional impairments in deficit and nondeficit forms of schizophrenia. (1997) (166)
Adrenal cortical activity in depressive illness. (1971) (165)
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. (2007) (164)
Early Insight and the Management of Schizophrenic Decompensation (1985) (164)
Next-generation negative symptom assessment for clinical trials: Validation of the Brief Negative Symptom Scale (2012) (161)
Patient response and resource management: another view of clozapine treatment of schizophrenia. (1995) (161)
Attenuated psychosis syndrome in DSM-5 (2013) (156)
Characteristic symptoms and outcome in schizophrenia. (1974) (150)
Cross-cultural evaluation of Schneider's first-rank symptoms of schizophrenia: a report from the International Pilot Study of Schizophrenia. (1974) (148)
Strong inference, theory testing, and the neuroanatomy of schizophrenia. (1993) (148)
Schizophrenia--time to commit to policy change. (2014) (146)
White Matter Alterations in Deficit Schizophrenia (2008) (144)
The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. (1977) (142)
Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis (2016) (141)
Attenuated psychosis syndrome: ready for DSM-5.1? (2014) (140)
Increased temporal lobe glucose use in chronic schizophrenic patients (1989) (140)
Borderline and schizophrenic patients: A comparative study. (1975) (140)
Prognosis of Brief Psychotic Episodes: A Meta-analysis. (2016) (137)
Another view of therapy for cognition in schizophrenia (2002) (132)
Correlations Between rCBF and Symptoms in Two Independent Cohorts of Drug-Free Patients with Schizophrenia (2006) (132)
Functional impairment in people with schizophrenia: Focus on employability and eligibility for disability compensation (2012) (131)
Borna disease virus and schizophrenia (1995) (129)
The deficit syndrome in the DSM-IV field trial: I. Alcohol and other drug abuse (1996) (127)
Schizoaffective Disorder in the DSM-5 (2013) (121)
Anticipating DSM-V: Should Psychosis Risk Become a Diagnostic Class? (2009) (119)
An investigation of the postpsychotic depressive syndrome. (1976) (118)
Signs and symptoms as predictors of outcome: a report from the International Pilot Study of Schizophrenia. (1978) (118)
The rationale and ethics of medication-free research in schizophrenia. (1997) (118)
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. (1993) (115)
Diazepam treatment of early signs of exacerbation in schizophrenia. (1999) (115)
Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. (1983) (114)
Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): I. Psychosis superspectrum (2020) (111)
The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. (2003) (109)
IMPACT OF THE SECLUSION ROOM EXPERIENCE (1976) (109)
Deficit and nondeficit forms of schizophrenia: Neuropsychological evaluation (1987) (106)
Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine. (1970) (106)
Depressive Symptoms and the Deficit Syndrome of Schizophrenia (1994) (105)
Does attitude toward psychosis relate to outcome? (1981) (105)
Time to clozapine response in a standardized trial. (1997) (103)
Autonomic nervous system activity in acute schizophrenia: I. method and comparison with normal controls. (1981) (102)
Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. (2001) (102)
Risk factors for the deficit syndrome of schizophrenia. (2000) (101)
Should attenuated psychosis syndrome be a DSM-5 diagnosis? (2011) (100)
A comparative trial of pharmacologic strategies in schizophrenia. (1987) (99)
Treatment outcomes in schizophrenia: implications for practice, policy, and research. (1995) (98)
Testing the Hypothesis of Accelerated Cerebral White Matter Aging in Schizophrenia and Major Depression (2013) (98)
The prognosis of schizophrenia: rationale for a multidimensional concept. (1978) (98)
Summer Birth and Deficit Schizophrenia: A Pooled Analysis From 6 Countries (2004) (96)
The Use of Clustering Techniques for the Classification of Psychiatric Patients (1972) (92)
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes (2003) (92)
Autonomic nervous system activity in acute schizophrenia: II. relationships to short-term prognosis and clinical state. (1981) (91)
Stability of the diagnosis of deficit syndrome in schizophrenia. (1999) (90)
The psychoses: Cluster 3 of the proposed meta-structure for DSM-V and ICD-11 (2009) (87)
Schizophrenia and stimulus intensity control. (1975) (87)
Deficit psychopathology and a paradigm shift in schizophrenia research (1999) (86)
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms (2004) (85)
Cortisol's Effects on Human Mental Functioning (1982) (84)
Will The Kraepelinian Dichotomy Survive DSM-V? (2009) (82)
Violence and schizophrenia. (2011) (81)
Borna disease virus antibodies and the deficit syndrome of schizophrenia (1997) (80)
Visual information-processing impairments in deficit and nondeficit schizophrenia. (1997) (79)
Clinical correlates of decreased anteroposterior metabolic gradients in positron emission tomography (PET) of schizophrenic patients. (1985) (79)
Schizophrenia: age at onset, gender and familial risk (1990) (76)
Platelet monoamine oxidase activity in acute schizophrenia. (1975) (75)
Lifetime psychotic symptoms assessed with the DIS. (1983) (72)
Maintenance therapy of persons with schizophrenia. (1996) (72)
A comparison of nine systems to diagnose schizophrenia (1982) (72)
Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models. (2015) (72)
Recovery from delusions. Three phases documented by patient's interpretation of research procedures. (1974) (71)
Sense And Nonsense (2014) (69)
Syndromes of Schizophrenia (1994) (68)
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. (2003) (68)
The diagnosis and understanding of schizophrenia. Part I. Use of signs and symptoms for the identification of schizophrenic patients. (1974) (66)
The deficit syndrome. (1994) (66)
EVOKED RESPONSE AND KINESTHETIC MEASURES OF AUGMENTING/REDUCING IN SCHIZOPHRENICS: REPLICATIONS AND EXTENSIONS (1976) (63)
The schizophrenia ketamine challenge study debate (1999) (61)
Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. (2013) (60)
An attempted integration of information relevant to schizophrenic subtypes. (1979) (60)
Risk Factors in Schizophrenia (1992) (59)
Immunoglobulins and Viral Antibodies in Psychiatric Patients (1978) (59)
Evaluating Signs and Symptoms: Comparison of Structured Interview and Clinical Approaches (1976) (58)
Assessing the Efficacy of Treatments for the Deficit Syndrome of Schizophrenia (2000) (58)
Another view of the history of antipsychotic drug discovery and development (2012) (57)
Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. (1999) (57)
Risk Factors in Schizophrenia: Season of Birth in Maryland, USA (1983) (55)
Reactive Psychosis I: Does the Pre‐DSM‐III Concept Define a Third Psychosis? (1988) (55)
Clinical constructs and therapeutic discovery (2004) (54)
Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia (2012) (54)
Subjective experience of schizophrenia. (1976) (54)
The risk of medication-free research. (1997) (53)
Schizophrenia heterogeneity revisited: Clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. (2018) (53)
Cortical structural abnormalities in deficit versus nondeficit schizophrenia (2012) (52)
6-Hydroxydopamine, noradrenergic reward, and schizophrenia. (1972) (49)
A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies (2012) (49)
DSM-5 status of psychotic disorders: 1 year prepublication. (2012) (47)
Lessons to take home from CATIE. (2008) (47)
Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. (1999) (46)
Methodologic standards for treatment outcome research in schizophrenia. (1981) (46)
The Treatment of Negative Symptoms: Pharmacological and Methodological Issues (1996) (46)
Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia (2003) (46)
Optimistic bias in the perception of personal risk: patterns in schizophrenia. (2005) (45)
Prospective study of prodromal symptoms in schizophrenic relapse. (1985) (45)
Integrating frequency and magnitude information in decision-making in schizophrenia: An account of patient performance on the Iowa Gambling Task. (2015) (44)
The negative symptom challenge. (1992) (44)
Clinical predictors of relapse following neuroleptic withdrawal (1992) (43)
Dihydropyrimidinase‐related protein 2 (DRP‐2) gene and association to deficit and nondeficit schizophrenia (2005) (43)
Monoamine Oxidase in Chronic Schizophrenia (1977) (43)
The power of analysis: Statistical perspectives. Part 2 (1988) (43)
The neuroanatomies of schizophrenia. (1997) (43)
Psychotic disorders in DSM-5: summary of changes. (2013) (42)
Neuroplasticity and schizophrenia (2004) (42)
Integration and sealing-over as recovery styles from acute psychosis. (1975) (41)
ART AND RECOVERY STYLE FROM PSYCHOSIS (1977) (41)
Multimodal white matter imaging to investigate reduced fractional anisotropy and its age-related decline in schizophrenia (2014) (41)
Issues of design and methodology in long-term followup studies. (1988) (41)
New Standards for Negative Symptom Assessment. (2015) (40)
Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia (2013) (39)
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia (2015) (39)
Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function (2009) (39)
Serotonin‐Dopamine Antagonists and Treatment of Negative Symptoms (1995) (38)
Reactive Psychosis II: Does DSM‐III‐R Define a Third Psychosis? (1988) (38)
Topographic differences between normals and schizophrenics: the N120 evoked potential component. (1986) (37)
Five year follow-up comparison of borderline and schizophrenic patients. (1977) (37)
Effects of short-term outcome and clinical improvement on reaction time in acute schizophrenia. (1978) (37)
Immunopathology and Viral Reactivation: A General Theory of Schizophrenia (1990) (36)
First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. (2005) (36)
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. (1995) (35)
Treatment‐relevant Subtypes of Schizophrenia (1981) (33)
Carbamazepine maintenance treatment in outpatient schizophrenics. (1991) (33)
Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. (2019) (33)
Diagnostic criteria for schizophrenia: Prognostic implications and diagnostic overlap (1980) (32)
The expert consensus guideline series (2009) (32)
Accuracy of the diagnoses of affective disorders and schizophrenia in public hospitals. (1988) (31)
Affective symptoms and the diagnosis of schizophrenia. (1979) (31)
Porous diagnostic boundaries: a new emphasis for the Bulletin. (2014) (30)
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia (2017) (30)
Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia. (2015) (30)
Beyond diagnosis: the phenomenology of schizophrenia. (1981) (29)
Olanzapine treatment of residual positive and negative symptoms (2003) (29)
Psychopathology and common sense (1991) (28)
A new setting for informed consent. (1974) (28)
Gluten sensitivity and relationship to psychiatric symptoms in people with schizophrenia (2014) (28)
One hundred years. (2011) (28)
First-Episode Schizophrenia (2012) (28)
Rethinking the Psychosis Threshold in Clinical High Risk (2018) (27)
Negative Symptom Therapeutics. (2017) (27)
The Extent of the Problem (1981) (26)
Testing trait depression as a potential clinical domain in schizophrenia (2014) (26)
Negative Symptoms: A Critique of Current Approaches (1991) (26)
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. (2008) (26)
Tth pseudotherapeutic community: an examination of antitherapeutics forces of psychiatric units. (1974) (25)
The therapeutic efficacy of hemodialysis in schizophrenia. (1983) (25)
Thoughts on the treatment of schizophrenia. (1986) (25)
Drs. McGlashan and Carpenter Reply (1976) (25)
Lack of association between COMT gene and deficit/nondeficit schizophrenia (2006) (25)
Sense and nonsense: an essay on schizophrenia research ethics (1999) (25)
Schizophrenia: syndromes and diseases. (1999) (24)
A test of the transmethylation hypothesis in acute schizophrenic patients. (1975) (24)
The diagnosis and understanding of schizophrenia. Summary and conclusions. (1974) (24)
Evidence-based treatment for first-episode schizophrenia? (2001) (24)
First- and second-generation antipsychotics: learning from CUtLASS and CATIE. (2007) (23)
Schizophrenia: disease, syndrome, or dimensions? (2007) (23)
Prognosis as the Critical Variable in Classification of the Functional Psychoses (1982) (23)
Long-term followup studies of schizophrenia: editors' introduction. (1988) (23)
How reliable is the psychiatric history? (1978) (23)
Association between polymorphism of the SNAP29 gene promoter region and schizophrenia (2005) (23)
Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study (2019) (22)
Maintaining informed consent validity during lengthy research protocols. (2007) (22)
Statistical issues in long-term followup studies. (1988) (22)
New directions in diagnosis: the longitudinal processes of schizophrenia. (1981) (22)
Attenuated Psychosis Syndrome: Need for Debate on a New Disorder (2014) (22)
The RDoC Controversy: Alternate Paradigm or Dominant Paradigm? (2016) (21)
Risk-taking in schizophrenia and controls with and without cannabis dependence (2015) (21)
Risperidone versus other atypical antipsychotic medication for schizophrenia (2000) (21)
The Limbic-Hypothalamic-Pituitary-Adrenal System and Human Behavior (1978) (21)
Current diagnostic concepts in schizophrenia. (1976) (20)
Statistical basis for exploring schizophrenia. (1981) (20)
The schizophrenia paradigm: a hundred-year challenge. (2006) (20)
Diazepam treatment of early symptoms of schizophrenic relapse. (1989) (19)
Targeted Maintenance Treatment in Schizophrenia (1996) (19)
The Schizophrenia Construct: Symptomatic Presentation (2011) (19)
The diagnosis and understanding of schizophrenia. Part II. Expanded perspectives for describing and comparing schizophrenic patients. (1974) (19)
Editorial: Traditional Ethics and New Sensitivities (2005) (18)
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients (1992) (18)
Early, targeted pharmacotherapeutic intervention in schizophrenia. (1986) (18)
Approaches to knowledge and understanding of schizophrenia. (1987) (18)
Clinical High Risk Controversies and Challenge for the Experts. (2018) (18)
Diagnostic Concepts in the Context of Clinical High Risk/Attenuated Psychosis Syndrome. (2015) (18)
Deconstructing and reconstructing illness syndromes associated with psychosis. (2007) (18)
The costs of drugs for schizophrenia. (2006) (17)
Schizophrenia: Disease Entity, Disease Entities, or Domains of Psychopathology (1995) (17)
Gas chromatographic-mass spectrometric identification of urinary bufotenin and dimethyltryptamine in drug-free chronic schizophrenic patients. (1974) (17)
RDoC and DSM-5: what's the fuss? (2013) (17)
Diurnal Rhythm of Cortisol in Mania (1971) (17)
Mazindol Treatment of Negative Symptoms (2000) (17)
The facts of schizophrenia: A personal commentary (2011) (16)
Shifting Paradigms and the Term Schizophrenia. (2016) (16)
A COMPARATIVE STUDY OF ART EXPRESSION OF SCHIZOPHRENIC, UNIPOLAR DEPRESSIVE, AND BIPOLAR MANIC‐DEPRESSIVE PATIENTS (1976) (16)
Why neuroleptic withdrawal in schizophrenia? (1995) (16)
At issue: A model for academic/industry collaboration. (2004) (16)
Diagnosis of schizophrenia: Consistency across information sources and stability of the condition (2012) (16)
A perspective on the psychotherapy of schizophrenia project. (1984) (15)
Zinc and copper in patients with schizophrenia. (1982) (15)
Anti gliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia (2018) (15)
Psychotic Disorders in DSM-5 (2013) (15)
Enhancing Psychosis-Spectrum Nosology Through an International Data Sharing Initiative. (2018) (15)
Targeting schizophrenia research to patient outcomes. (2006) (15)
Effect of neuroleptic withdrawal on plasma prolactin: A possible marker of receptor adaptation (1989) (15)
Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication. (1998) (14)
Olanzapine treatment of residual positive and negative symptoms. (2005) (14)
Integrating treatments in schizophrenia. (1986) (14)
Hypothesis testing: Is clozapine's superior efficacy dependent on moderate D2 receptor occupancy? (1998) (13)
Further examination of a biochemical test for suicide potential. (1976) (13)
It is time for a new paradigm for the Study of Psychoses. (2010) (13)
Drug development and the deficit syndrome of schizophrenia (1995) (12)
Criticism of the DSM-V risk syndrome: A rebuttal (2011) (12)
Risperidone versus typical antipsychotic medication for schizophrenia (2000) (12)
First-rank symptoms or rank-and-file symptoms? Commentary (1996) (11)
Clarifying Standards for Using Placebos (2003) (11)
Commentary on the Soteria project: misguided therapeutics. (2002) (11)
Primary psychosis: more to know, much more to do (2021) (11)
Concepts and methods when considering negative symptom course (2015) (10)
Conceptualizing schizophrenia through attenuated symptoms in the population. (2010) (10)
Schizophrenia: Positive and Negative Symptoms and Syndromes (1991) (9)
7. Psychopathology and the question of neurodevelopmental or neurodegenerative disorder (1991) (9)
The challenge to psychiatry as society's agent for mental illness treatment and research. (1999) (9)
Treatment, services, and environmental factors. (1988) (9)
From clinical trial to prescription. (2002) (9)
Functioning at the clinical-research interface: the clinical-research meeting. (1975) (9)
Multivariate statistics and meaning in the study of psychopathology. (1983) (8)
The deficit syndrome: functional and structural characteristics (1991) (8)
Developmental Interactive Framework for Psychotic Disorders. (2017) (8)
Participants with schizophrenia retain the information necessary for informed consent during clinical trials. (2013) (8)
Psychotherapy in hospitalized research patients. (1975) (8)
Diagnosis and treatment of depression in late life: the NIH Consensus Development Conference Statement. (1993) (8)
Diagnostic Categories: Provisional, Not Otherwise Classified, or Place-holder? (2016) (8)
Autonomic variables related to short-term outcome and clinical improvement in acute schizophrenia. (1979) (8)
The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study (2017) (8)
Attenuated psychosis syndrome: benefits of explicit recognition (2015) (7)
Clinically Meaningful Gaps Between Clinical Trials and Patient Treatment. (2018) (7)
Early Detection of Psychosis Vulnerability: Progress, Opportunity, and Caution. (2016) (7)
A comparison of symptom provocation procedures in psychiatry and other areas of medicine: implications for their ethical use in research (2001) (7)
The DSM‐III Diagnosis of Schizophrenic‐Like Illness and the Clinical: Pharmacology of Psychosis (1982) (7)
Novel neuroleptic dosage reduction strategies (1992) (7)
How the Diagnosis of Schizophrenia Impeded the Advance of Knowledge (and What to Do About It) (2013) (7)
The Role for Psychodynamic Psychiatry in the Treatment of Schizophrenic Patients (1980) (7)
On Schizophrenia and New Generation Drugs (2000) (7)
Reconceptualizing schizophrenia in the Hierarchical Taxonomy Of Psychopathology (HiTOP) (2022) (7)
A few methodologic issues of note. (2008) (7)
Editorial Board Changes for 2018. (2018) (6)
An Affective Neuroscience Model of Impaired Approach Motivation in Schizophrenia. (2016) (6)
New diagnostic issues in schizophrenic disorders. (1995) (6)
Medication-Free Research and Patient Safety (1998) (6)
New drug treatment strategies in schizophrenia: editorial introduction. (1983) (6)
A dilemma born of progress: switching from clozapine to a newer antipsychotic. (1999) (6)
Misunderstandings about Attenuated Psychosis Syndrome in the DSM-5 (2014) (6)
Television in the hospital: programming patients' delusions. (1976) (6)
Social withdrawal as psychopathology of mental disorders (2017) (6)
Clozapine conflict [6] (1996) (5)
[The deficit syndrome: a domain of schizophrenia]. (1998) (5)
Editorial: Evidence-Based Therapeutics—Introducing the Cochrane Corner (2007) (5)
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993. (2000) (5)
Attenuated Psychosis Syndrome: A New Diagnostic Class? (2015) (5)
Commentaries on “First-Rank Symptoms or Rank-and-File Symptoms?” (1996) (5)
Resurrection of the Follow-Back Method to Study the Transdiagnostic Origins of Psychosis (2021) (5)
Structure of the Psychotic Disorders Classification in DSM-5. (2016) (5)
Schizophrenia and dialysis. (1983) (5)
Crisis and emergency on the psychiatric ward. (1974) (5)
A postscript on the 12-Point Flexible System for the diagnosis of schizophrenia: A report from the international pilot study of schizophrenia (1980) (5)
The long-term stability of the deficit syndrome (1996) (5)
Dopamine agents for the treatment of the negative symptoms of schizophrenia (1995) (5)
449 Prefrontal cortex in schizophrenia: A magnetic resonance imaging study using anatomically relevant landmarks (1997) (4)
Which Aspects of Heterogeneity Are Useful to Translational Success (2013) (4)
The psychoses in DSM-5 and in the near future. (2013) (4)
Placebo-controlled Studies in Schizophrenia: Ethical and Scientific Perspectives. Panel Discussion (1999) (4)
Postpsychotic depression [7] (1991) (4)
Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge. (2007) (4)
A drug-free month for outpatient schizophrenics. (1978) (4)
Things I Do Not Like. (2018) (4)
Diagnostic systems and prognostic validity. (1980) (4)
Summer birth and deficit schizophrenia: A pooled analysis from five countries (2003) (4)
A Randomized Clinical Trial of Oxytocin or Galantamine in Schizophrenia: Assessing the Impact on Behavioral, Lexical, and Self-Report Indicators of Social Affiliation (2020) (4)
Does Research Interfere with Patient Care (1975) (4)
Editorial: More Changes for the Schizophrenia Bulletin (2007) (4)
Borna disease virus antibodies and schizophrenia (1995) (4)
Domains of psychopathology: Concept and validity (1993) (4)
Fifty Years: Do Over or Move Forward. (2017) (4)
Ideology and Scientific Progress: First-Rank Symptoms. (2019) (4)
The neuroanatomy of the deficit syndrome (1992) (4)
Schizophrenia: A view of immediate future (2021) (4)
Psychotic Disorders in DSM-5: Clinical Implications of Revisions From DSM-IV (2016) (4)
An approach to the diagnosis and understanding of schizophrenia. Introduction. (1974) (4)
Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge. (2002) (3)
A Virus-Associated Immunopathological Theory of Schizophrenia (1991) (3)
472 Blood flow activation differences during an auditory task in schizophrenic patients with and without primary negative symptoms (1997) (3)
Schizophrenia: changing the name and broadening the concept is problematic (2016) (3)
Schedule for the Deficit Syndrome (2015) (3)
The deficit form of schizophrenia (1989) (3)
Interpersonal and pharmacologic treatment in schizophrenia: a comparative study of new approaches. (1986) (3)
Evidence-based therapeutics--introducing the Cochrane corner. (2007) (3)
Early intervention: how early and with what? (2015) (3)
Placebo effect in depression. (2009) (3)
Changes Ahead for the Bulletin in 2013 (2013) (3)
The Future of Schizophrenia Pharmacotherapeutics: Not So Bleak (2012) (3)
New views on the course and treatment of schizophrenia. (1998) (3)
Manuscript Rejection for the Schizophrenia Bulletin: Some Reasons (2010) (3)
Deconstructing Schizophrenia (2017) (3)
Dr. Carpenter and Associates Reply. (1977) (3)
The Neuroanatomy of Schizophrenia: Editors' Introduction (1997) (3)
Clozapine treatment in schizophrenic outpatients: Preliminary results from a double-blind efficacy study (1991) (2)
Criticism vs Fact: A Response To A Warning Sign on the Road to DSM-V by Allen Frances, MD (2009) (2)
DSM-V: NEW PARADIGMS AND OTHER CONTROVERSIES (2010) (2)
rCBF pattern differences between medication-free schizophrenic patients with and without deficit symptoms (1996) (2)
The key clinical dimensions of the functional psychoses. (1975) (2)
Clozapine conflict. (1996) (2)
Commentary: psychosocial treatment of schizophrenia. (1993) (2)
Progress on NIMH initiatives (memorial theme for Wayne Fenton, MD). (2007) (2)
Schizophrenia neuroanatomy and theory falsification (1991) (2)
The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G. (2020) (2)
Testability and group phenomenon in schizophrenia. (1977) (2)
Questions about rapid treatment. (1977) (2)
Improving decisional capacity for informed consent in schizophrenia (2003) (2)
Classification Is Essential for the Attenuated Psychosis Syndrome (2020) (2)
The Neurobiology of Negative Symptoms and the Deficit Syndrome (2009) (2)
Challenge to atypical antipsychotic drug effect on cognition. (2007) (2)
John S. Strauss and schizophrenia: Early discovery, lasting impact (2016) (2)
Methodological Issues in the Study of Outcome (1977) (2)
Experience with a drug-free month in schizophrenic outpatients. (1985) (2)
Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia. (2020) (2)
What is schizophrenia? (1983) (2)
T191. RANDOMIZED DOUBLE-BLIND FEASIBILITY STUDY OF A GLUTEN-FREE DIET IN PEOPLE WITH SCHIZOPHRENIA AND ELEVATED ANTIGLIADIN ANTIBODIES (AGA IGG) (2018) (2)
Is deficit schizophrenia a disease entity? (2000) (2)
Strauss Carpenter Levels of Functioning Scale (1995) (1)
THE PSYCHOSIS HIGH RISK STATE: IS IT VALID? (2014) (1)
Assessment and diagnosis (1981) (1)
Clinical psychopathology: Kurt Schneider. Translated by M. W. Hamilton. Grune & Stratton, New York, 1959, 173 pages. Reviewed by Salvatore Muleh and William T. Carpenter, Jr (1974) (1)
Imipramine and Clonazepam for Panic Disorder (1989) (1)
Response to Rietdijk et al. Letter (2011) (1)
An Interactive Developmental Systems Model of Schizophrenia (1981) (1)
19 Are psychopathologic domains independent diseases? (1997) (1)
Organizing Knowledge in the Biopsychosocial Medical Model (2017) (1)
Classical Schizophrenia: Liddle and the Core of Schizophrenia (2019) (1)
Book Review Schizophrenia into Later Life: Treatment, Research, and Policy Edited by Carl I. Cohen. 322 pp. Washington, D.C., American Psychiatric Publishing, 2003. $36. 1-58562-037-8. (2003) (1)
Lifetime Psychotic Symptoms Assessed With the DIS: The Authors Reply (1984) (1)
Psychological and Psychophysiological Models of Schizophrenia: Discussion (1987) (1)
A Hundred-Year Challenge (2006) (1)
Schizophrenia 35 years ago in the Journal of Nervous and Mental Disease: past and future of the schizophrenia spectrum concept. (2012) (1)
Commentary on "how to break the logjam in schizophrenia: a look beyond genetics" by Joseph Zubin and Stuart Steinhauer. (1981) (1)
RESEARCH IN UNMEDICATED PATIENT POPULATIONS: INSIGHTS INTO THE NEUROBIOLOGY OF SCHIZOPHRENIA (2014) (1)
Antipsychotic Medications: Flawed Concepts and Ethics. (2020) (1)
Relapse Risk Assessment for Schizophrenia Patients (RASP): A New Self-Report Screening Tool. (2017) (1)
Neural Circuits in Schizophrenia-Reply (1994) (1)
Clozapine in schizophrenic outpatients: Efficacy, longterm outcome, and relationship to prefrontal cortex (1993) (1)
Review of the Tarrytown Conference (1987) (1)
Traditional ethics and new sensitivities. (2006) (1)
The masks of insanity: a graphics tool for the summarization of psychiatric data. (1977) (1)
122. High Antigliadin Antibodies (IgG) are Linked to Peripheral and Central Measures of Inflammation in a Subset of People With Schizophrenia (2017) (1)
Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone (2006) (1)
Estrogen treatment in women with schizophrenia (2005) (1)
Behavioral effects of cortisol in man. (1971) (1)
Non-neuroleptic treatment of prodromal symptoms (1993) (1)
Oxytocin and sexual function in males and females with schizophrenia (2018) (1)
RNA profiling on the anterior cingulate in schizophrenia (2003) (1)
Empathy and schizophrenia. (1989) (1)
GeneS and Schizophrenia Genes and Schizophrenia : From a Festschrift Seminar honoring (2014) (1)
Current concepts in schizophrenia: international symposia report new standards for assessment and treatment. Part I: Pathophysiology research prompts assessment updates. (1995) (1)
Evaluating New Pharmacotherapies for Schizophrenia (2016) (1)
Avolition, Negative Symptoms, and a Clinical Science Journey and Transition to the Future. (2016) (1)
A schizophrenic patient who resists phenothiazines. (1983) (1)
Schizophrenia: The Facts (1983) (0)
The Journal for Psychoses and Related Disorders. (2016) (0)
[No Title] (2004) (0)
Letter on “ethical problems in psychiatric research” (1998) (0)
S.13.04 Effects of intranasal oxytocin or galantamine for primary enduring negative symptoms and cognitive impairments in people with schizophrenia (2015) (0)
NOVEL USES OF TYPICAL NEUROLEPTICS (1984) (0)
Reply (2003) (0)
Decisional capacity and informed consent (2000) (0)
Letter: The training of psychiatrists. (1976) (0)
A virus-mediated alpha interferon immunopathological theory of schizophrenia (1989) (0)
Borna disease virus and schizophrenia: Preliminary results (1991) (0)
Ensuring informed consent in research with co-occurring serious mental illness and substance use disorders: The modified evaluation to sign consent (2007) (0)
5. RETHINKING THE TAXONOMY, COURSE, AND OUTCOME OF PSYCHOSES: DIMENSIONAL, LATENT TRAJECTORY, AND TRANSDIAGNOSTIC APPROACHES (2018) (0)
Etiologies of Schizophrenia: Psychological and Social (1981) (0)
Book Review Contemporary Issues in the Treatment of Schizophrenia Edited by Christian L. Shriqui and Henry A. Nasrallah. 863 pp. Washington, D.C., American Psychiatric Press, 1995. $95. 0-88048-681-3 (1995) (0)
C.18.03 Advances in therapeutic treatment of negative and cognitive symptoms of schizophrenia: comprehensive and long-term treatment (2007) (0)
A glimpse forward regarding psychopathology of psychotic disorders (2020) (0)
Olanzapine for schizophrenia (2000) (0)
The New York State Community Support System: A Profile of Clients (1984) (0)
Genetic counseling of psychotic disorders (1989) (0)
The new challenges in psychopathology. (1991) (0)
Things I Wish. (2022) (0)
Dr. Green and Associates Reply (1991) (0)
The Concept of Schizophrenia (1981) (0)
Reactive Psychoses (1982) (0)
The nurse's role in informed consent. (1975) (0)
Medical-claims databases in the design of a health-outcomes comparison of quetiapine (`Seroquel' 1 Seroquel is a trademark, the property of Zeneca Limited. 1 ) and usual-care antipsychotic medication (1998) (0)
The effect of dosage interval on the efficacy of fluphenazine decanoate in the prevention of relapse (1993) (0)
DSM-V Updated Guidelines (2010) (0)
The interaction of diagnostic and outcome variables in schizophrenic patients (1976) (0)
The influence of menstrual cycle fluctuations in sex hormones on hemispheric asymmetry in women with schizophrenia (2005) (0)
New style clinical trials in schizophrenia (1999) (0)
A Brief Review of Organic Diseases Masquemdhg as Functional Illness (1983) (0)
Drs. Heinrichs and Carpenter Reply (1986) (0)
Treatments: Guidelines and Modalities (1981) (0)
Treatments: General Principles (1981) (0)
"Ethical problems in psychiatric research". (1998) (0)
Schizophrenia Outcomes Functioning Interview--Informant Version (2012) (0)
Attenuated psychosis syndrome: benefits of explicit recognition •Forum• Attenuated psychosis syndrome (2015) (0)
Research Domain Criteria: Controversial Paradigm (2020) (0)
The Clinical-Legal Interface in Schizophrenia (1981) (0)
rCBF pattern contrasts between normal volunteers and medication-free schizophrenics derived from a difficult tone recognition task (1996) (0)
Who is culpable? The insanity defense. (1983) (0)
Schizophrenia Outcomes Functioning Interview--Patient Version (2012) (0)
Editorial: The Wayne Fenton Award and First Awardee (2007) (0)
Remembering 2 Heroes of Philanthropy. (2016) (0)
Major Announcement: Schizophrenia Bulletin Open. (2019) (0)
Abstracts for the Sixth Biennial SIRS Conference (2018) (0)
SU17. Oxytocin and Sexual Function in Males and Females With Schizophrenia (2017) (0)
A Few Changes and New Directions for the Bulletin (2005) (0)
The challenge study controversy (2000) (0)
22. THE NEAR FUTURE FOR SCHIZOPHRENIA (PSYCHOSIS) RESEARCH (2018) (0)
Letter: Does research interfere with patient care? (1975) (0)
Schizophrenia as a Brain Disease (1984) (0)
A phenomenological test of the validity of the deficit syndrome (1991) (0)
Negative Symptoms: A Brief Story and Advances in Spain. (2022) (0)
Thomas Hanlon (2017) (0)
Methods for diagnosis and therapy of schizophrenia (2003) (0)
SHOULD WE CONTINUE TO DO PLACEBO-CONTROLLED MEDICATION TRIALS IN SCHIZOPHRENIA? AN ETHICO-CLINICAL DEBATE (2014) (0)
What is Missing in Treatment Guidelines? (2021) (0)
DEBATE: ATTENUATED PSYCHOSIS SYNDROME: A NEW DIAGNOSTIC CLASS IS NEEDED (2014) (0)
A prospective study of the costs of care for patients with schizophrenia (2005) (0)
Drug abuse among deficit and nondeficit schizophrenic patients in the DSM-IV field trials (1995) (0)
10. NEW PARADIGMS FOR DISCOVERY (2019) (0)
Drugs 2005; 65 (8): 1113-1138 (2005) (0)
DSM-5: Is Risk Syndrome Category Needed? (2010) (0)
Beyond Diagnostic Criteria (1981) (0)
FORUM – QUANTITATIVE CLASSIFICATIONOFMENTAL DISORDER : PROGRESS AND CHALLENGES Progress in achieving quantitative classi fi cation of psychopathology (2018) (0)
Molecular Medicine and the Prospects for Prevention and Early Intervention in Schizophrenia (2004) (0)
A technique for evaluating clinical equivalence (1986) (0)
PL.03 The schizophrenia paradigm: a hundred-year challenge (2007) (0)
An alpha interferon theory of schizophrenia (1989) (0)
Expressed Emotion (EE) and the targeted medication approach (1991) (0)
Impact of Treatment on the Core Deficit Pathology (1996) (0)
Cannabis and psychosis. (2004) (0)
PL.03.01 The schizophrenia paradigm: a hundred-year challenge (2009) (0)
THE EVALUATION OF OUTCOME IN SCHIZOPHRENIA (2011) (0)
rCBF pattern differences between schizophrenic patients with and without enduring negative symptoms (deficit symptoms) (1995) (0)
The Perspectives of Psychiatry (1986) (0)
The cost of relapse in schizophrenia: a comprehensive 2 year retrospective audit (2005) (0)
Glucose metabolism in deficit and non-deficit schizophrenic patients (1993) (0)
Clinical correlates of prolactin concentration in outpatient schizophrenics (1989) (0)
A View to the Future (2005) (0)
Quality of Life Scale (QLS) 1984 (2012) (0)
Etiologies of Schizophrenia (1981) (0)
Carbamazepine treatment of schizophrenia (1989) (0)

This paper list is powered by the following services:

Other Resources About William T. Carpenter

en.wikipedia.org

What Schools Are Affiliated With William T. Carpenter?

William T. Carpenter is affiliated with the following schools:

William T. Carpenter's Academic­Influence.com Rankings